News

Apply Now: 📣 BLUE KNIGHT ™️ Resident QuickFire Challenge: Accelerating Project NextGen

Johnson & Johnson Innovation, together with the Biomedical Advanced Research and Development Authority (BARDA), is proud to launch the BLUE KNIGHT™ Resident QuickFire Challenge: Accelerating Project NextGen.

Current and alumni Blue Knight residents and their collaborators are invited to submit promising potential pre-clinical or clinical solutions for the opportunity to receive award funding from a total pool of $10M to help them accelerate their potential vaccines, therapeutics, and enabling technologies.

Applicants can apply to one or both application tracks:

  • Partner: Forging collaborations can accelerate evidence generation to get to key inflection points, allowing for more rapidly deployable potential solutions that provide mutual value. For the ‘Partner’ track of this challenge, Blue Knight residents who choose to collaborate with another Blue Knight or early-stage company in their submission may apply through a joint application submission.*
  • Sole Contributor: Blue Knight residents are invited to apply to accelerate their potential solution.**

All awards are subject to the execution of the necessary (award) agreements.

*Applicants must have at least one Blue Knight resident, current or alumni, as a collaborator
**Applicants must be current or alumni Blue Knight residents

 

Learn more here.

Recent News

06/23/2026

Scout Space raises Series A second close from VTC Ventures, Long Knife, and 100KM

Scout Space, a space domain awareness sensor and software provider, has announced the second close of its Series A financing, adding VTC Ventures, Long Knife and 100KM to its investor syndicate. The initial close occurred in May 2026, led by Washington Harbour Partners. The funding will accelerate deployment of Scout’s in-orbit sensor network, support upcoming

06/22/2026

Icarus Medical Secures $7.2 Million Series A to Accelerate Growth and Innovation

Icarus Medical, a Charlottesville-based med-tech company focused on advancing orthopedic bracing technology, today announced the successful close of its Series A financing round. Originally targeting $5 million, the round closed oversubscribed at $7.2 million, reflecting strong investor confidence in the company’s technology platform, market momentum, and long-term vision. Orthopedic bracing company Icarus Medical closes oversubscribed

06/16/2026

Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that the Company’s Compensation Committee and Board of Directors granted Matthew Davidson and Julie Saiki, the Company’s newly appointed chief development officer and executive vice president of strategy, respectively, restricted stock units and stock options to purchase Company common stock as an inducement to